Sickle cell disease (SCD) was first described in the USA over 100 years ago [1]. Nearly six decades ago, SCD became known as the first molecular disease after Linus Pauling described the different electrophoretic movements of hemoglobin A compared to hemoglobin S [2]. In the 1970s, research funding for SCD significantly increased, and findings from those research studies allowed SCD to move from a nearly universally fatal disease of childhood to a chronic illness [3]. Today, there are nearly 100,000 children and adults in the USA alone with SCD and millions more worldwide [4]. Although hydroxyurea and blood transfusion therapy decrease many SCD-associated complications, they are often underutilized in developing countries and neither cure the disease. Patients with SCD experience multisystem complications including recurrent and painful vaso-occlusive crises, acute chest syndrome, stroke, splenic sequestration, and pulmonary hypertension. As a result, organ damage begins at a young age and is progressive, contributing to an average life expectancy of SCD patients that is half that of the general population [5, 6]. Even though life expectancy of patients has improved in the last several decades in the developed world, very high childhood mortality rates (50–90%) exist in underdeveloped countries of Africa and India where the vast majority of SCD patients are globally. SCD remains a highly morbid disease that causes chronic and progressive physical damage, as well as poorer overall quality of life for affected children and adults worldwide.

Currently, the only available cure for SCD is hematopoietic stem cell transplant (HSCT). Successful transplants in children with SCD additionally result in organ damage reversal or stabilization of CNS vasculopathy. When a matched sibling donor is available for SCD patients, HSCT has excellent overall survival (93%, 95% confidence interval 91.1–94.6%) and good event free survival (91%, 95% confidence interval 89.6–93.3%) [7]. HSCT, however, is still vastly underutilized, even for those with donors; in fact, just over 1000 transplants for SCD patients have been documented in the literature[7]. Since SCD affects nearly 100,000 children and adults in the USA alone, and millions more worldwide, considerably less than 1% of people effected by SCD have been cured. Causes for the low numbers of HSCT performed for SCD patients are multifactorial and
include concern about toxicities from conditioning regimens or graft-versus-host
disease, lack of provider or family awareness of HSCT as a curative option for
SCD, and, most importantly, lack of an available suitable donor. This has led to
the field investigating less toxic conditioning regimens (reduced intensity), novel
graft manipulation techniques and medications to prevent graft-versus-host dis-
ease, and donor options other than matched siblings referred to as alternative
donors. While outcomes with alternative donor transplants still need to be opti-
mized, encouraging progress with unrelated bone marrow, umbilical cord blood,
and most recently half-HLA-matched (haploidentical) parents and siblings has
led to the majority of patients having a transplant donor option. Probably the most
exciting advance in the HSCT for the SCD field in the last decade has been the
ability to transplant adults with SCD using very low intensity conditioning and
HLA-matched donors [8, 9]. The success rate of approximately 88% with no
graft-versus-host disease is remarkable especially in a patient group that for many
decades were considered too sick to proceed to transplant. Although the concept
that gene therapy may ameliorate human genetic diseases emerged in the 1970s,
this field of medical research experienced many obstacles over the last three and
a half decades which prolonged the translation of this genetic technology into
clinical medicine. However, along with these obstacles came broadened knowl-
dge of safe gene delivery and editing systems which carved the path to making
the concept of gene therapy to alleviate human diseases such as SCD a reality.
Gene therapy trials in SCD are now underway, and very preliminary results show
promise [10]. Unlike HSCT, gene therapy offers the potential of curative therapy
to virtually all people affected by SCD.

This book aims to provide a comprehensive, state-of-the art review of HSCT
for SCD and serves as a valuable resource for clinicians and researchers with an
interest in SCD as well as HSCT. The book reviews new data about risk predic-
tion for severe SCD; presents unique challenges of HSCT for patients with SCD;
profiles the supportive care guidelines for SCD patients who are undergoing
HSCT; highlights our current understanding of the best transfusion support for
SCD patients prior to, during, and after HSCT; and provides new perspectives
about the ethics of HSCT for pediatric patients with SCD. Several landmark
phase III trials that utilized matched unrelated and haploidentical donors for
HSCT in SCD patients have been placed in context with respect to current
management.

We hope that this book will serve as a useful resource for physicians and research-
ers interested in this challenging, yet exciting, curative therapy for SCD. We thank
the authors who contributed chapters to this book. We dedicate this book to our
spouses, children, parents, and other family members who have supported us
throughout our careers. We also thank our mentors who inspired us to continue
working to improve the care of children with SCD and their families: Drs. Naomi
Luban, Jeffery L. Miller, Derek Persons, and Naynesh Kamani. We also dedicate
this book to our patients who live with this debilitating disease and inspire our work
with their strength, resilience, and fighting spirits.
References


Indianapolis, IN, USA
Atlanta, GA, USA
Washington, DC, USA

Emily Riehm Meier
Ross M. Fasano
Allistair Abraham
Sickle Cell Disease and Hematopoietic Stem Cell Transplantation
Meier, E.R.; Abraham, A.; Fasano, R.M. (Eds.)
2018, XIII, 334 p. 21 illus., 16 illus. in color., Hardcover
ISBN: 978-3-319-62327-6